In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Is MRI-stress testing the new gold standard? A systematic review and meta-analysis on the diagnostic performance of cardiac imaging methods for the detection of relevant coronary artery stenosis

Session Poster session 1

Speaker Sebastian Maximilian Haberkorn

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Imaging - Other
  • Session type : Poster Session
  • FP Number : P188

Authors : S M Haberkorn (Duesseldorf,DE), S I Bueter (Duesseldorf,DE), M Kelm (Duesseldorf,DE), G Hopkin (London,GB)

Authors:
S M Haberkorn1 , S I Bueter1 , M Kelm1 , G Hopkin2 , 1Universityhospital Duesseldorf, Cardiology, Pneumology and Angiology - Duesseldorf - Germany , 2London School of Economics and Political Science, Health Politics - London - United Kingdom of Great Britain & Northern Ireland ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii148

Background: An early and accurate detection of relevant coronary artery disease (CAD) is crucial for an effective and efficient therapy. Besides invasive measurements, such as conventional coronary angiography (CCA) and a fractional-flow-reserve (FFR)-assessment, several myocardial imaging methods coexist to non-invasively determine the severity of CAD.

Objectives: This study aimed to systematically assess and to compare the diagnostic performance of stress myocardial perfusion imaging (sMRI) and dobutamine stress-echocardiography (DSE) for the non-invasive diagnosis of relevant CAD through a meta-analysis of the existing evidence using conventional invasive methods as the reference standard.

Search methods: The data bases of MEDLINE, EMBASE and the Cochrane Library have been searched for literature evaluating either sMRI, DSE or both for the diagnosis of relevant CAD. The meta-analysis has been performed based on Cochrane guidelines.

Selection criteria: A study was included if (1) CCA or FFR was used as a reference standard for diagnosing of relevant CAD, defined as >70% stenosis respectively <0.80 pressure gradient in hyperaemia; (2) sufficient data to permit analysis and to reconstruct contingency tables (explicitly true-positive, false-positive, false-negative and true-negative findings) was provided; (3) there was a minimal sample size of 20 patients; (4) stress-perfusion was facilitated using either adenosine or regadenoson, respectively dobutamine; and (5) the studies was of prospective design.

Data collection and analysis: From the 5.634 studies identified, 1.306 relevant articles were selected after title screening. Just 47 fulfilled all inclusion criteria on full-text review, resulting in a total sample size of 4.742 patients. Data extraction was performed for each study by two reviewers independently.Pooled analysis was performed based on a random effects models. 

Results: The sensitivity, specificity and diagnostic odds ratio (DOR) for sMRI were 0.88 (95% CI: 0.85-0.90), 0.84 (95% CI: 0.81-0.87), and 38 (95% CI: 29-49), respectively 0.72 (95% CI: 0.61-0.81), 0.89 (95% CI: 0.83-0.93), and 20 (95% CI: 9-46) for DSE. Post-test probability was augmented by positive (likelihood ratio) LR of 5.5 (95% CI: 4.7-6.5) and negative LR of 0.14 (95% CI: 0.12-0.18) based on Bayes’ theorem, as compared to LR of 6.3 (95% CI: 3.8, 10.4) and negative LR of 0.31 (95% CI: 0.21, 0.46) for DSE. The size of the prediction region on the hierarchical summary receiver operating characteristic (HSROC) plot for sMRI (0.2894; 95 % CI 0.1087–0.7703) was significantly smaller compared to the one of DSE (1.0665; 95 % CI 0.2721–4.1938; p<0.01).

Conclusion: The results of this systematic review and meta-analysis attest sMRI a superior diagnostic performance of relevant CAD compared to DSE and can refine the post-test probability of CAD.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are